Literature DB >> 22871592

Deficiency of cathepsin S attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice.

Yanwen Qin1, Xu Cao, Jun Guo, Yaozhong Zhang, Lili Pan, Hongjia Zhang, Huihua Li, Chaoshu Tang, Jie Du, Guo-Ping Shi.   

Abstract

AIMS: Abdominal aortic aneurysm (AAA) is characterized by extensive aortic wall matrix degradation that contributes to the remodelling and eventual rupture of the arterial wall. Elastinolytic cathepsin S (Cat S) is highly expressed in human aneurysmal lesions, but whether it contributes to the pathogenesis of AAA remains unknown. METHODS AND
RESULTS: AAAs were induced in apolipoprotein E (ApoE) and Cat S compound mutant (Apoe(-/-)Ctss(-/-)) mice and in ApoE-deficient Cat S wild-type littermates (Apoe(-/-)Ctss(+/+)) by chronic angiotensin II infusion, and AAA lesions were analysed after 28 days. We found that Cat S expression increased significantly in mouse AAA lesions. The AAA incidence in Apoe(-/-)Ctss(-/-) mice was much lower than that in Apoe(-/-)Ctss(+/+) mice (10 vs. 80%). Cat S deficiency significantly reduced external and luminal abdominal aortic diameters, medial elastin fragmentation, and adventitia collagen content. Cat S deficiency reduced aortic lesion expression and the activity of matrix metalloproteinase (MMP)-2, MMP-9, and Cat K, but not the activity of other major cathepsins, such as Cat B and Cat L. Absence of Cat S significantly reduced AAA lesion media smooth muscle cell (SMC) apoptosis, lesion adventitia microvessel content, and inflammatory cell accumulation and proliferation. In vitro studies proved that Cat S helps promote SMC apoptosis, angiogenesis, monocyte and T-cell transmigration, and T-cell proliferation--all of which are essential to AAA pathogenesis.
CONCLUSIONS: These data provide direct evidence that Cat S plays an important role in AAA formation and suggest that Cat S is a new therapeutic target for human AAA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22871592      PMCID: PMC3500043          DOI: 10.1093/cvr/cvs263

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  50 in total

Review 1.  Lysosomal cysteine cathepsins: signaling pathways in apoptosis.

Authors:  Veronika Stoka; Vito Turk; Boris Turk
Journal:  Biol Chem       Date:  2007-06       Impact factor: 3.915

2.  The aneurysm detection and management study screening program: validation cohort and final results. Aneurysm Detection and Management Veterans Affairs Cooperative Study Investigators.

Authors:  F A Lederle; G R Johnson; S E Wilson; E P Chute; R J Hye; M S Makaroun; G W Barone; D Bandyk; G L Moneta; R G Makhoul
Journal:  Arch Intern Med       Date:  2000-05-22

3.  Cystatin C deficiency in human atherosclerosis and aortic aneurysms.

Authors:  G P Shi; G K Sukhova; A Grubb; A Ducharme; L H Rhode; R T Lee; P M Ridker; P Libby; H A Chapman
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

4.  Participation of a cathepsin L-type protease in the activation of caspase-3.

Authors:  R Ishisaka; T Utsumi; T Kanno; K Arita; N Katunuma; J Akiyama; K Utsumi
Journal:  Cell Struct Funct       Date:  1999-12       Impact factor: 2.212

Review 5.  Review of current theories for abdominal aortic aneurysm pathogenesis.

Authors:  Ian M Nordon; Robert J Hinchliffe; Peter J Holt; Ian M Loftus; Matthew M Thompson
Journal:  Vascular       Date:  2009 Sep-Oct       Impact factor: 1.285

6.  Leukocyte cathepsin S is a potent regulator of both cell and matrix turnover in advanced atherosclerosis.

Authors:  R de Nooijer; I Bot; J H von der Thüsen; M A Leeuwenburgh; H S Overkleeft; A O Kraaijeveld; R Dorland; P J van Santbrink; S H van Heiningen; M M Westra; P T Kovanen; J W Jukema; E E van der Wall; Th J C van Berkel; G P Shi; E A L Biessen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-12-18       Impact factor: 8.311

7.  In vitro induction of regulatory T cells by anti-CD3 antibody in humans.

Authors:  Michal Abraham; Arnon Karni; Adi Dembinsky; Ariel Miller; Roopali Gandhi; David Anderson; Howard L Weiner
Journal:  J Autoimmun       Date:  2008 Feb-Mar       Impact factor: 7.094

8.  Formation of extracellular matrix-digesting invadopodia by primary aortic smooth muscle cells.

Authors:  Emilia Furmaniak-Kazmierczak; Scott W Crawley; Rhonda L Carter; Donald H Maurice; Graham P Côté
Journal:  Circ Res       Date:  2007-04-19       Impact factor: 17.367

Review 9.  Cathepsin cysteine proteases in cardiovascular disease.

Authors:  Suzanne P M Lutgens; Kitty B J M Cleutjens; Mat J A P Daemen; Sylvia Heeneman
Journal:  FASEB J       Date:  2007-05-23       Impact factor: 5.191

10.  Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice.

Authors:  Jiusong Sun; Galina K Sukhova; Min Yang; Paul J Wolters; Lindsey A MacFarlane; Peter Libby; Chongxiu Sun; Yadong Zhang; Jian Liu; Terri L Ennis; Rebecca Knispel; Wanfen Xiong; Robert W Thompson; B Timothy Baxter; Guo-Ping Shi
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

View more
  41 in total

Review 1.  Monocytes and macrophages in abdominal aortic aneurysm.

Authors:  Juliette Raffort; Fabien Lareyre; Marc Clément; Réda Hassen-Khodja; Giulia Chinetti; Ziad Mallat
Journal:  Nat Rev Cardiol       Date:  2017-04-13       Impact factor: 32.419

Review 2.  Cysteinyl cathepsins in cardiovascular diseases.

Authors:  Xian Zhang; Songyuan Luo; Minjie Wang; Guo-Ping Shi
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2020-01-09       Impact factor: 3.036

3.  Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects.

Authors:  Christopher D Payne; Mark A Deeg; Melanie Chan; Lai Hock Tan; Elizabeth Smith LaBell; Tong Shen; David J DeBrota
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

4.  Discovery of Cathepsin S Inhibitor LY3000328 for the Treatment of Abdominal Aortic Aneurysm.

Authors:  Prabhakar K Jadhav; Matthew A Schiffler; Kostas Gavardinas; Euibong J Kim; Donald P Matthews; Michael A Staszak; D Scott Coffey; Bruce W Shaw; Kenneth C Cassidy; Richard A Brier; Yuke Zhang; Robert M Christie; William F Matter; Keyun Qing; Jim D Durbin; Yong Wang; Gary G Deng
Journal:  ACS Med Chem Lett       Date:  2014-08-27       Impact factor: 4.345

5.  Cathepsin K Deficiency Ameliorates Systemic Lupus Erythematosus-like Manifestations in Faslpr Mice.

Authors:  Yi Zhou; Huimei Chen; Li Liu; Xueqing Yu; Galina K Sukhova; Min Yang; Vasileios C Kyttaris; Isaac E Stillman; Bruce Gelb; Peter Libby; George C Tsokos; Guo-Ping Shi
Journal:  J Immunol       Date:  2017-01-16       Impact factor: 5.422

6.  Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology.

Authors:  Mark J Osborn; Beau R Webber; Ronald T McElmurry; Kyle D Rudser; Anthony P DeFeo; Michael Muradian; Anna Petryk; Benedikt Hallgrimsson; Bruce R Blazar; Jakub Tolar; Elizabeth A Braunlin
Journal:  J Inherit Metab Dis       Date:  2016-10-14       Impact factor: 4.982

7.  Selective cathepsin S inhibition attenuates atherosclerosis in apolipoprotein E-deficient mice with chronic renal disease.

Authors:  Jose-Luiz Figueiredo; Masanori Aikawa; Chunyu Zheng; Jacob Aaron; Lilian Lax; Peter Libby; Jose Luiz de Lima Filho; Sabine Gruener; Jürgen Fingerle; Wolfgang Haap; Guido Hartmann; Elena Aikawa
Journal:  Am J Pathol       Date:  2015-02-10       Impact factor: 4.307

8.  Plasma levels of cathepsins L, K, and V and risks of abdominal aortic aneurysms: a randomized population-based study.

Authors:  Bing-Jie Lv; Jes S Lindholt; Jing Wang; Xiang Cheng; Guo-Ping Shi
Journal:  Atherosclerosis       Date:  2013-07-14       Impact factor: 5.162

Review 9.  Cysteine protease cathepsins and matrix metalloproteinases in the development of abdominal aortic aneurysms.

Authors:  Yanwen Qin; Xu Cao; Yaoguo Yang; Guo-Ping Shi
Journal:  Future Cardiol       Date:  2013-01

10.  IL-17A promotes ventricular remodeling after myocardial infarction.

Authors:  Su-Feng Zhou; Jing Yuan; Meng-Yang Liao; Ni Xia; Ting-Ting Tang; Jing-Jing Li; Jiao Jiao; Wen-Yong Dong; Shao-Fang Nie; Zheng-Feng Zhu; Wen-Cai Zhang; Bing-Jie Lv; Hong Xiao; Qing Wang; Xin Tu; Yu-Hua Liao; Guo-Ping Shi; Xiang Cheng
Journal:  J Mol Med (Berl)       Date:  2014-06-27       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.